Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial We provide solutions for
lung cancer screening
and early detection
iDNA-logo-white Lung_screening_IDNA Read more
Slide iDNA-logo-white Only one 5-minute
visit for 80% of
participants
Read more
iDNA-our-solutions-header iDNA-our-solutions-header iDNA-logo-white Our solution provides
safe reassurance for 98%
of participants
Read more

LIFE CHANGING EARLY DETECTION: WE WANT TO ACCELERATE IMPLEMENTATION AND MAKE LUNG CANCER SCREENING ACCESSIBLE FOR THOSE WHO BENEFIT.

ABOUT iDNA

“Life changing early detection.” Up to now medical doctors were in most instances only able to extend the lives of people diagnosed with lung cancer. This is because lung cancer is almost always diagnosed in a late stage where survival rates are very low: nine out of ten persons that are diagnosed with a stage 4 lung cancer tumour will not be alive in five years. There have been big advancements in medication and treatment in the last decades, but due to the late stage diagnosis, these advancements were mainly live-extending and not live-saving. Recently, the results of the NELSON trial were published in the New England Journal of Medicine, showing low-dose CT-scans could detect lung cancer in an early stage and thereby reduce lung cancer mortality by 24% in males in a high-risk population (for the abstract, click on the image to the right). Therefore, the institute for DiagNostic Accuracy (iDNA) wants to accelerate high quality implementation and make lung cancer screening accessible for those who benefit.

Besides lung cancer screening, we have recently also engaged in helping in the fight against the COVID-19 pandemic. Check out our news item below or the article to the far right.

FEATURED NEWS

Most cited paper of 2017 in European Radiology!

Most cited paper of 2017 in European Radiology! 600 400 iDNA

Another moment worth celebrating for iDNA! An article published in European Radiology, of which prof. Oudkerk was supervisor and co-author, has recently received the award for most cited article of…

Working to find solutions for COVID-19

Working to find solutions for COVID-19 2560 1476 iDNA

iDNA against COVID-19 To address the current Covid-19 challenges, the Dutch National Institute for Health and Environment (RIVM) has formally requested Prof. Oudkerk to bring together a group of key…

Lung_screening_IDNA

NELSON: A successful early detection trial shown to reduce lung cancer mortality in (ex) smokers

NELSON: A successful early detection trial shown to reduce lung cancer mortality in (ex) smokers 1920 1440 iDNA

Having a potential impact of saving 60,000-80,000 people with lung cancer per year within Europe The scientific article ‘’Reduced Lung Cancer Mortality with Volume CT Screening in the NELSON trial”…

Lung_screening_IDNA

Less Is More in Lung Cancer Risk Prediction Models

Less Is More in Lung Cancer Risk Prediction Models 1920 1440 iDNA

In an invited commentary for JAMA Network Open, Marjolein Heuvelmans, MD, PhD, together with prof. Oudkerk, commented on current developments in the field of lung cancer screening risk prediction modelling.…


OUR SOLUTIONS

Privacy Preferences

When you visit our website, it may store information through your browser from specific services, usually in the form of cookies. Here you can change your Privacy preferences. It is worth noting that blocking some types of cookies may impact your experience on our website and the services we are able to offer.

Click to enable/disable Google Analytics tracking code.
Click to enable/disable Google Fonts.
Click to enable/disable Google Maps.
Click to enable/disable video embeds.
Our website uses cookies to remember your preferences (e.g. the language of the website)